Teva Boasts a Several Billion Dollar NTE Opportunity
publication date: Aug 1, 2013
Revenue potential from the launch of new therapeutic entities (NTEs) in coming years should more than offset troubles from the loss of exclusivity of Copaxone.
To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.